One concern about the medications, however, is that Now, a large-scale study has found no significant increase in thyroid cancer risk for people with type 2 diabetes on GLP-1 agonists compared with people treated with The study appears in Bjrn Pasternak, MD, PhD, lead author, and principal researcher at the Department of Medicine, Solna, at Karolinska Institutet in Sweden, explained why the team conducted the the study
For amifostine, subcutaneous injection is more helpful in reducing side effects compared to intravenous administration (128)
What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
Many patients start to feel improvements within a couple of days, while others may take longer to notice changes